Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies

The hedgehog (Hh) signaling pathway has been identified as important to normal embryonic development in living organisms and it is implicated in processes including cell proliferation, differentiation and tissue patterning. Aberrant Hh pathway has been involved in the pathogenesis and chemotherapy resistance of different solid and hematologic malignancies. Basal cell carcinoma (BCC) and medulloblastoma are two well-recognized cancers with mutations in components of the Hh pathway. Vismodegib has recently approved as the first inhibitor of one of the components of the Hh pathway (smoothened). This review attempts to provide current data on the molecular pathways involved in the development of BCC and the therapeutic options available for the treatment of locally advanced and metastatic BCC, and the new targeted therapies in development.

[1]  D. Lev,et al.  Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. , 2001, American journal of medical genetics.

[2]  J. Stewart,et al.  Metastatic basal cell carcinoma: report of a case responding to chemotherapy. , 1980, Postgraduate medical journal.

[3]  E. Zackai,et al.  Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. , 2003, Journal of the National Cancer Institute.

[4]  David Hogg,et al.  Mutations in SUFU predispose to medulloblastoma , 2002, Nature Genetics.

[5]  M. Luxenberg,et al.  Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Jefford,et al.  Metastatic basal cell carcinoma: rapid symptomatic response to Cisplatin and Paclitaxel , 2004, ANZ journal of surgery.

[7]  D. T. Robles,et al.  An unusual case of Bloom syndrome presenting with basal cell carcinoma. , 2009, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[8]  Kristine Rose,et al.  Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. , 2011, The Journal of investigative dermatology.

[9]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[10]  O. Hansen,et al.  Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. , 1996, Acta oncologica.

[11]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.

[12]  Barbara Stecca,et al.  Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. , 2010, Journal of molecular cell biology.

[13]  Jean Kanitakis,et al.  Genetic skin diseases predisposing to basal cell carcinoma. , 2012, European journal of dermatology : EJD.

[14]  Jing Yuan,et al.  Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.

[15]  Tannishtha Reya,et al.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.

[16]  F. Passarelli,et al.  Bazex-Dupré-Christol syndrome: an ectodermal dysplasia with skin appendage neoplasms. , 2009, European journal of medical genetics.

[17]  B. Zelger,et al.  Palliative therapy of giant basal cell carcinoma with the monoclonal anti‐epidermal growth factor receptor antibody cetuximab , 2008, The British journal of dermatology.

[18]  J. Utikal,et al.  Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. , 2001, European journal of cancer.

[19]  L. F. Fajardo,et al.  Metastatic basal cell carcinoma. A review. , 1970, Archives of pathology.

[20]  Christopher J. Arpey,et al.  Aggressive basal cell carcinoma: Presentation, pathogenesis, and management , 2004, Cancer and Metastasis Reviews.

[21]  J. D. Harmon,et al.  Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin , 1985, Cancer.

[22]  S. Seidenari,et al.  Identification of Muir–Torre syndrome among patients with sebaceous tumors and keratoacanthomas , 2005, Cancer.

[23]  Z. Modrušan,et al.  Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. , 2011, Cancer research.

[24]  L. Hovelius,et al.  Report of Five Cases , 1977 .

[25]  C. Rudin,et al.  A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Kris Chang,et al.  Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. , 2012, The New England journal of medicine.

[27]  R. Ashinoff,et al.  Rombo syndrome: a second case report and review. , 1993, Journal of the American Academy of Dermatology.

[28]  T. Woodcock,et al.  Responsiveness of metastatic basal‐cell carcinoma to chemotherapy. A case report , 1983, Cancer.

[29]  M. Christian,et al.  Metastatic Basal Cell Carcinoma Presenting as Unilateral Lymphedema , 1998, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[30]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[31]  M. Wolter,et al.  Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. , 1997, Cancer research.

[32]  Jeremy Stinson,et al.  Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.

[33]  C. Dirksen,et al.  Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. , 2008, The Lancet. Oncology.

[34]  Andrew Shenton,et al.  Basal Cell Carcinomas in Gorlin Syndrome: A Review of 202 Patients , 2010, Journal of skin cancer.

[35]  Frank Cirrone,et al.  Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. , 2012, Clinical therapeutics.

[36]  A. Chang,et al.  Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. , 2013, JAMA dermatology.

[37]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[38]  P. Westermark,et al.  The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. , 1981, Acta dermato-venereologica.

[39]  David W. Bray,et al.  Amelanotic melanoma in a patient with Rothmund-Thomson syndrome. , 2008, Archives of dermatology.

[40]  H. von Domarus,et al.  Metastatic basal cell carcinoma , 1984 .

[41]  S. Patra,et al.  Intricacies of hedgehog signaling pathways: a perspective in tumorigenesis. , 2012, Experimental cell research.

[42]  Jun O. Liu,et al.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. , 2010, Cancer cell.

[43]  N. Haites,et al.  A Scottish family with Bazex-Dupré-Christol syndrome: follicular atrophoderma, congenital hypotrichosis, and basal cell carcinoma. , 1996, Journal of medical genetics.

[44]  Q. Gu,et al.  Activating Smoothened mutations in sporadic basal-cell carcinoma , 1998, Nature.

[45]  K. Kotkow,et al.  Corrigendum to “GDC-0449—A potent inhibitor of the hedgehog pathway” [Bioorg. Med. Chem. Lett. 19 (2009) 5576] , 2010 .

[46]  Tannishtha Reya,et al.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.

[47]  C. Hui,et al.  Negative regulation of Gli1 and Gli2 activator function by Suppressor of fused through multiple mechanisms. , 2005, Differentiation; research in biological diversity.

[48]  A. Kessinger,et al.  Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. , 2011, Cancer treatment reviews.

[49]  G. Jemec,et al.  Nonmelanoma skin cancer in organ transplant patients. , 2003, Transplantation.

[50]  R. Benjamin,et al.  Clinical phase I-II study of cis-dichloro-diammineplatinum(II) given by continuous lv infusion. , 1978, Cancer treatment reports.

[51]  D. Kuijpers,et al.  Basal Cell Carcinoma , 2002, American journal of clinical dermatology.

[52]  A. Krešo,et al.  Cancer Stem Cells and Self-renewal , 2010, Clinical Cancer Research.

[53]  W. Matsui,et al.  Hedgehog pathway as a drug target: Smoothened inhibitors in development , 2012, OncoTargets and therapy.

[54]  C. Blanpain,et al.  Identification of the cell lineage at the origin of basal cell carcinoma , 2010, Nature Cell Biology.

[55]  K. Kotkow,et al.  GDC-0449-a potent inhibitor of the hedgehog pathway. , 2009, Bioorganic & medicinal chemistry letters.

[56]  P. Steijlen,et al.  A case of Rombo syndrome , 2001, The British journal of dermatology.

[57]  Lixin Lang,et al.  A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. , 2010 .

[58]  C. Rudin,et al.  Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.

[59]  C. Rudin,et al.  Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  P. LoRusso,et al.  Review: Targeting the Hedgehog pathway in cancer , 2010, Therapeutic advances in medical oncology.

[61]  K. Niemi,et al.  The Bazex Syndrome: follicular atrophoderma with multiple basal cell carcinomas, hypotrichosis and hypohidrosis , 1981, Clinical and experimental dermatology.

[62]  C. Huff,et al.  A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma, , 2011 .

[63]  K. Anderson,et al.  Mouse Kif7/Costal2 is a cilia-associated protein that regulates Sonic hedgehog signaling , 2009, Proceedings of the National Academy of Sciences.

[64]  Jean Y. Tang,et al.  Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma. , 2011, Seminars in cutaneous medicine and surgery.

[65]  P. Beachy,et al.  Teratogen-mediated inhibition of target tissue response to Shh signaling. , 1998, Science.

[66]  J. Low,et al.  The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment , 2010, Clinical Cancer Research.

[67]  J. Frank,et al.  Multiple familial and pigmented basal cell carcinomas in early childhood – Bazex–Dupré–Christol syndrome , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[68]  J. Feyzi,et al.  Metastatic basal cell carcinoma. Report of five cases , 1994, Cancer.

[69]  M. Leverkus,et al.  Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive Disease , 2010, Journal of skin cancer.

[70]  F. D. de Sauvage,et al.  Clinical experience with Hedgehog pathway inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  B. Chevallier,et al.  [Metastatic basal cell carcinoma]. , 1993, Annales de dermatologie et de venereologie.

[72]  Raoul Tibes,et al.  Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. , 2009, The New England journal of medicine.